CS
KROS icon

Candriam SCA’s Keros Therapeutics KROS Stock Holding History

Candriam SCA’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-345,384
Closed -$20.1M – 692
2024
Q3 		$20.1M Sell
345,384
-96,471
-22% -$4.76M 0.12% 178
2024
Q2 		$20.2M Sell
441,855
-210,144
-32% -$11.3M 0.12% 167
2024
Q1 		$43.2M Sell
651,999
-167,063
-20% -$9.91M 0.28% 82
2023
Q4 		$32.6M Buy
819,062
+78,001
+11% +$2.45M 0.22% 100
2023
Q3 		$23.6M Buy
741,061
+20,000
+3% +$747K 0.17% 120
2023
Q2 		$29M Sell
721,061
-23,996
-3% -$1.05M 0.21% 124
2023
Q1 		$29.3M Buy
745,057
+119,143
+19% +$6.02M 0.2% 123
2022
Q4 		$30.1M Buy
625,914
+264,125
+73% +$12.3M 0.2% 117
2022
Q3 		$13.6M Hold
361,789
– – 0.1% 214
2022
Q2 		$9.99M Sell
361,789
-58,881
-14% -$2.58M 0.08% 225
2022
Q1 		$22.9M Buy
420,670
+179,724
+75% +$9.23M 0.16% 148
2021
Q4 		$14.1M Hold
240,946
– – 0.09% 218
2021
Q3 		$9.53M Buy
240,946
+139,537
+138% +$4.97M 0.06% 282
2021
Q2 		$4.31M Buy
+101,409
New +$5.49M 0.03% 437

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Candriam SCA's KROS Position: Q4 2024 in Review

Candriam SCA sold out of Keros Therapeutics (KROS) in Q4 2024, closing a stake of 345,384 shares — an estimated $20.1M sold.

Candriam SCA first reported a position in KROS in Q2 2021 and held it in 14 quarters. The position peaked at $43.2M in Q1 2024. 161 funds tracked by Wall St. Rank hold KROS as of Q4 2024.

  • Candriam SCA reported no remaining Keros Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Candriam SCA sold 345,384 Keros Therapeutics shares in Q4 2024, an estimated $20.1M.
  • Candriam SCA first reported a position in Keros Therapeutics in Q2 2021 and held it in 14 quarters.
  • Candriam SCA's Keros Therapeutics position peaked at $43.2M in Q1 2024.
  • 161 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2024.

Based on Candriam SCA's 13F filing for Q4 2024, filed 7 Feb 2025.